Clinical Trial Update: Study of Pegylated Human Recombinant Arginase for Liver Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of pegylated human recombinant arginase for hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Pegylated human recombinant arginase (pegylated arginase)

Snippet

Sponsor: Bio-Cancer Treatment International Limited | Conditions: Neoplasm, Hepatocellular Carcinoma | Phase 1 | Status: COMPLETED